Anna-Bettina Haidich1, John P A Ioannidis. 1. Clinical Trials and Evidence-Based Medicine Unit, Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina 45110, Greece.
Abstract
OBJECTIVE: Clinical sites participating in multicenter trials may have unequal performance in recruiting subjects. We propose using the Gini coefficient as a quantitative measure of site accrual inequalities. STUDY DESIGN AND SETTING: We evaluated the relationship of this metric to other study characteristics across 166 clinical studies (27,865 subjects) conducted by the AIDS Clinical Trials Group between 1986 and 1999. RESULTS: Overall there was a modest recruitment inequality among clinical centers (mean Gini=0.33). In multivariate modeling, site accrual inequalities were higher when there was more protracted enrollment, and a larger number of sites and were lower in antiretroviral studies than other studies. In long-term studies, the site accrual inequality increased significantly over time (P=0.004). In efficacy trials, a higher Gini coefficient was associated with higher likelihood of the study results being statistically significant (P=0.010). CONCLUSION: The Gini coefficient may be easily and routinely incorporated in the description of the characteristics of a clinical study and may provide insights about its enrollment pattern.
OBJECTIVE: Clinical sites participating in multicenter trials may have unequal performance in recruiting subjects. We propose using the Gini coefficient as a quantitative measure of site accrual inequalities. STUDY DESIGN AND SETTING: We evaluated the relationship of this metric to other study characteristics across 166 clinical studies (27,865 subjects) conducted by the AIDS Clinical Trials Group between 1986 and 1999. RESULTS: Overall there was a modest recruitment inequality among clinical centers (mean Gini=0.33). In multivariate modeling, site accrual inequalities were higher when there was more protracted enrollment, and a larger number of sites and were lower in antiretroviral studies than other studies. In long-term studies, the site accrual inequality increased significantly over time (P=0.004). In efficacy trials, a higher Gini coefficient was associated with higher likelihood of the study results being statistically significant (P=0.010). CONCLUSION: The Gini coefficient may be easily and routinely incorporated in the description of the characteristics of a clinical study and may provide insights about its enrollment pattern.
Authors: Fawaz Al Ammary; Alvin G Thomas; Allan B Massie; Abimereki D Muzaale; Ashton A Shaffer; Brittany Koons; Mohamud A Qadi; Deidra C Crews; Jacqueline Garonzik-Wang; Hai Fang; Daniel C Brennan; Krista L Lentine; Dorry L Segev; Macey L Henderson Journal: Am J Transplant Date: 2019-02-08 Impact factor: 8.086
Authors: Christoph Westerwalbesloh; Alexander Grünberger; Wolfgang Wiechert; Dietrich Kohlheyer; Eric von Lieres Journal: Microb Biotechnol Date: 2017-04-03 Impact factor: 5.813
Authors: Dinesh Pal Mudaranthakam; Alexandra Brown; Elizabeth Kerling; Susan E Carlson; Christina J Valentine; Byron Gajewski Journal: JMIR Form Res Date: 2021-12-22